HK1064099B - 血小板腺核苷二磷酸(adp)受體抑制劑 - Google Patents
血小板腺核苷二磷酸(adp)受體抑制劑 Download PDFInfo
- Publication number
- HK1064099B HK1064099B HK04106901.1A HK04106901A HK1064099B HK 1064099 B HK1064099 B HK 1064099B HK 04106901 A HK04106901 A HK 04106901A HK 1064099 B HK1064099 B HK 1064099B
- Authority
- HK
- Hong Kong
- Prior art keywords
- amino
- alkyl
- chloro
- sulfonyl
- mmol
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HK07102667.1A HK1096088B (zh) | 2001-08-02 | 2004-09-10 | 血小板腺核苷二磷酸(adp)受體抑制劑 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/920,325 US6906063B2 (en) | 2000-02-04 | 2001-08-02 | Platelet ADP receptor inhibitors |
| US09/920,325 | 2001-08-02 | ||
| PCT/US2002/023909 WO2003011872A1 (en) | 2001-08-02 | 2002-07-25 | Platelet adp receptor inhibitors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK07102667.1A Division HK1096088B (zh) | 2001-08-02 | 2004-09-10 | 血小板腺核苷二磷酸(adp)受體抑制劑 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK07102667.1A Addition HK1096088B (zh) | 2001-08-02 | 2004-09-10 | 血小板腺核苷二磷酸(adp)受體抑制劑 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1064099A1 HK1064099A1 (zh) | 2005-01-21 |
| HK1064099B true HK1064099B (zh) | 2007-05-25 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1412364B1 (en) | Platelet adp receptor inhibitors | |
| EP1257550B1 (en) | Platelet adp receptor inhibitors | |
| AU2004278030B2 (en) | 2,4-Dioxo-3-quinazolinylaryl sulfonylureas | |
| AU2001264566A1 (en) | Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors | |
| HK1064099B (zh) | 血小板腺核苷二磷酸(adp)受體抑制劑 | |
| HK1157331B (zh) | 血小板adp受體抑制劑 | |
| HK1096088B (zh) | 血小板腺核苷二磷酸(adp)受體抑制劑 | |
| US20040029867A1 (en) | Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors |